ADARx Pharmaceuticals (ADRX) is trading down at $12.79 (-9.68%) on NASDAQ, as of the latest quote. It operates in the sector.
One firm's current price target on ADARx Pharmaceuticals: $32 — 150% above the current $12.8. Each is tracked to its date and scored the same way a member's call is.
1 target, newest first. Open a row for its source and scoring.
Entry price $17.7, the close nearest Oct 20, 2026, when the target was reported; the target is +81% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 20, 2027.
with an overweight rating and a price target of $32.00
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| Q1 FY27Jun 2026 | Q2 FY27Sep 2026 | |
|---|---|---|
| Income statement | ||
| Revenue | — | $2.22M |
| Operating income | — | −$32.2M |
| Operating margin | — | −1451.4% |
| Net income | −$25.8M | −$28.1M |
| Net margin | — | −1268.2% |
| EPS (diluted) | — | −$1.74 |
| Balance sheet | ||
| Cash and equivalents | — | $570.6M |
| Total assets | — | $929.1M |
| Total liabilities | — | $354.7M |
| Shareholders' equity | −$251.1M | $574.4M |
From ADARx Pharmaceuticals's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →
Read at PR Newswire ↗ Link to this story
Also mentions Regeneron Pharmaceuticals, Novo Nordisk